rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Senseonics Holdings, Inc.

SENS · Nasdaq

Health CareLife-science toolsLeading

SENS stood above a rising 150-day average in 9 of the last 52 weekly readings, including each of the last 9 weeks. It is 15.2% above that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+1 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
9 in a row
Industry in uptrend
52% +1 in 4 wk
Insider buys, 12 months
$1.2M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
108 (+24)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 9 of 52 weeks.

21 Apr – 20 Oct
27%44%61%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$386KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months8
Sale orders, 12 months0
Buyers · sellers4 · 0
WhoDidSharesTraded
Douglas A. RoederDirectorbought13,953.284at $8.9819 Aug 2026filed 20 Aug 2026
Douglas A. RoederDirectorbought22,686at $5.5612 May 2026filed 13 May 2026
Douglas A. RoederDirectorbought17,500at $5.7313 Mar 2026filed 16 Mar 2026
Timothy T. GoodnowPresident and CEObought17,225at $5.7913 Mar 2026filed 16 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders108+24 on the quarter
New · exited44 · 20
Reported value$120.4M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Sessa Capital IM, L.P.added · filed 14 Aug 20264,437,532$25.2M+2,671,439+151.3%
BlackRock, Inc.added · filed 7 Aug 20262,793,558$15.9M+2,224,829+391.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,779,398$10.1M+162,201+10.0%
Avidity Partners Management LPnew · filed 14 Aug 20261,600,000$9.1M+1,600,000
Sio Capital Management, LLCadded · filed 14 Aug 20261,592,692$9.0M+1,476,908+1275.6%
UBS Group AGadded · filed 13 Aug 20261,487,429$8.4M+1,039,200+231.8%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,132,210$6.4M+665,695+142.7%
MASTERS CAPITAL MANAGEMENT LLCadded · filed 14 Aug 2026700,000$4.0M+200,000+40.0%
STATE STREET CORPadded · filed 7 Aug 2026511,117$2.9M+330,836+183.5%
MARSHALL WACE, LLPreduced · filed 13 Aug 2026405,695$2.3M-58,680−12.6%
31 Mar 2023 – 30 Jun 2026
84112139Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Douglas A. Roeder Company insiderDirector · last 1 Oct 20269 · 11
Douglas S. Prince Company insiderDirector · last 1 Oct 20260 · 1
Edelman Steven Company insiderDirector · last 1 Oct 20261 · 1
Edward Fiorentino Company insiderDirector · last 1 Oct 20260 · 2
Brian B. Hansen Company insiderChief Commercial Officer · last 15 Jun 20260 · 0
Francine Kaufman Company insiderChief Medical Officer · last 15 Jun 20260 · 4
Frederick T. Sullivan Company insiderChief Financial Officer · last 15 Jun 20262 · 0
Kenneth L. Horton Company insiderGC & Corp. Development Advisor · last 15 Jun 20260 · 1
Mukul Jain Company insiderChief Operating Officer · last 15 Jun 20260 · 14
Timothy T. Goodnow Company insiderPresident and CEO · last 15 Jun 20264 · 4
Sharon Larkin Company insiderDirector · last 20 May 20260 · 1
Stephen P. DeFalco Company insiderDirector · last 20 May 20260 · 2

Same industry

OABI OmniAbLeading+75%
TXG 10x GenomicsLeading+61%
AVTR AvantorLeading+48%
ILMN IlluminaLeading+46%
RVTY RevvityLeading+39%
MASS 908 DevicesLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202544.7%
Operating profit marginFY 2025 · to 31 Dec 2025-194%
Free cash flow marginFY 2025 · to 31 Dec 2025-171%
Return on capital employedFY 2025 · to 31 Dec 2025-67.0%
Debt to equityFY 2025 · to 31 Dec 20250.58×
Interest coverFY 2025 · to 31 Dec 2025-13.80×
Research spendFY 2025 · to 31 Dec 202589.6%
Share count trendFY 2025 · to 20 Feb 20261.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$40.2M
Free cash flowFY 2025 · to 31 Dec 2025−$60.2M

Analyst forecasts

No analyst forecasts yet.